Skip to main content Skip to navigation
Anti-HLA-DR Purified
Product Details
Down Arrow Up Arrow


BD™
MHC class II antigen; HLA class II histocompatibility antigen
Human
Mouse IgG2a, κ
Human lymphoblastoid B-cell line RPMI 8866
Flow cytometry
25 μg/mL
20 μL
Phosphate buffered saline with gelatin and 0.1% sodium azide.
ASR


Preparation And Storage

Store vials at 2° to 8°C. Conjugated forms should not be frozen and should be protected from exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.

340857 Rev. 1
Antibody Details
Down Arrow Up Arrow
L243

The Anti-HLA-DR antibody, clone L243, is derived from the hybridization of NS-1/1-Ag4 mouse myeloma cells with spleen cells isolated from BALB/c mice immunized with the human lymphoblastoid B-cell line RPMI 8866.

The Anti-HLA-DR antibody recognizes a human class II major histocompatibility complex (MHC) antigen. The antigen is a transmembrane glycoprotein composed of α- and β-subunits that have molecular weights of 36 and 27 kilodaltons (kDa), respectively.

340857 Rev. 1
Format Details
Down Arrow Up Arrow
Purified
Tissue culture supernatant is purified by either protein A/G or affinity purification methods. Both methods yield antibody in solution that is free of most other soluble proteins, lipids, etc. This format provides pure antibody that is suitable for a number of downstream applications including: secondary labeling for flow cytometry or microscopy, ELISA, Western blot, etc.
Purified
340857 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "340857" on CiteAb

Development References (11)

  1. Brodsky FM. A matrix approach to human class II histocompatibility antigens: reactions of four monoclonal antibodies with the products of nine haplotypes.. Immunogenetics. 1984; 19(3):179-94. (Biology). View Reference
  2. Edwards JA, Durant BM, Jones DB, Evans PR, Smith JL. Differential expression of HLA class II antigens in fetal human spleen: relationship of HLA-DP, DQ, and DR to immunoglobulin expression.. J Immunol. 1986; 137(2):490-7. (Biology). View Reference
  3. Engleman EG, Warnke R, Fox RI, Dilley J, Benike CJ, Levy R. Studies of a human T lymphocyte antigen recognized by a monoclonal antibody.. Proc Natl Acad Sci USA. 1981; 78(3):1791-5. (Biology). View Reference
  4. Lampson LA, Levy R. Two populations of Ia-like molecules on a human B cell line.. J Immunol. 1980; 125(1):293-9. (Biology). View Reference
  5. Levacher M, Tallet S, Dazza MC, Dournon E, Rouveix B, Pocidalo JJ. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.. Clin Exp Immunol. 1990; 81(2):177-82. (Biology). View Reference
  6. Stites DP, Casavant CH, McHugh TM, et al. Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.. Clin Immunol Immunopathol. 1986; 38(2):161-77. (Biology). View Reference
  7. Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990; 48(2):138-148. (Biology). View Reference
  8. Tomkinson BE, Wagner DK, Nelson DL, Sullivan JL. Activated lymphocytes during acute Epstein-Barr virus infection.. J Immunol. 1987; 139(11):3802-7. (Biology). View Reference
  9. Warnke R, Miller R, Grogan T, Pederson M, Dilley J, Levy R. Immunologic phenotype in 30 patients with diffuse large-cell lymphoma.. N Engl J Med. 1980; 303(6):293-300. (Biology). View Reference
  10. Warnke RA, Levy R. Detection of T and B cell antigens with hybridoma monoclonal antibodies: a biotinavidin-horseradish peroxidase method. J Histochem Cytochem. 1980; 28:771-776. (Biology).
  11. Zipf RF, Fox R, Dilley J, Levy R. Definition of the high risk ALL patient by immunologic phenotyping withmonoclonal antibodies. Cancer Res. 1981; 41:4786. (Biology).
View All (11) View Less
340857 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

Analyte Specific Reagent. Analytical and performance characteristics are not established.

Analyte Specific Reagent. Analytical and performance characteristics are not established.

 

Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.